

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Bakhit, et al.  
 Customer No.: 51957  
 Serial No.: 10/521,367  
 Filed: January 12, 2005  
 For: **COMPOSITIONS AND METHODS  
 COMPRISING PROSTAGLANDIN RELATED  
 COMPOUNDS AND TREFOIL FACTOR FAMILY  
 PEPTIDES FOR THE TREATMENT OF  
 GLAUCOMA WITH REDUCED HYPEREMIA**

Group Art Unit: 1609  
 Confirmation No. 2266  
 Examiner: GiGi Huang  
 FILED ELECTRONICALLY

Commissioner for Patents  
 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Reply to the Office Action dated February 27, 2007 on the above-identified application.

[X]           Reply (4 pages)  
 [X]           The fee has been calculated as shown below:

<i>CLAIMS</i>	<b>COLUMN A</b> <i>Claims Remaining After Amendment</i>	<b>COLUMN B</b> <i>Highest Number Previously Paid</i>	<b>COLUMN C</b> <i>Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
<i>Total</i>	20	28	0	x \$50	\$0.00
<i>Independent</i>	3	3	0	x \$200	\$0.00
[ ] First Presentation of Multiple Dep. Claim x \$280 = \$0.00					\$0.00
Time Extension Fees:					\$0.00
<b>Total Due:</b>					<b>\$0.00</b>

The Commissioner is hereby authorized to charge payment of extension fees or any other fees required, or credit any overpayment, to Deposit Account No. 01-0885.

Respectfully submitted,

Date: March 26, 2007

/Brent A. Johnson/  
 Brent A. Johnson  
 Registration No. 51,851  
 Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson  
 Allergan, Inc. (T2-7H)  
 2525 Dupont Drive  
 Irvine, CA 92612  
 Telephone: 714/246-4348  
 Telecopier: 714/246-4249